Kaos Capital today issued a letter to its fellow Capricor Therapeutics (NASDAQ: CAPR) shareholders calling on them to support an immediate meeting with the Board of Directors regarding the Company’s future strategic direction.
According to its press release, Kaos Capital intends, subject to applicable law and the Company’s governing documents, to nominate two independent directors and to seek a Board-led M&A and Strategic Alternatives Committee chaired by a shareholder-backed director.
The full text of Kaos Capital’s open letter to Capricor shareholders is available here.
